This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering



AULBIO is engaged globally in the research/development and commercialization of highly technical company located in South Korea. We have developed an optimal drug delivery system using injectable biodegradable microspheres. AULBIO's Long-acting injectable microsphere technology is a very simple process, and has excellent reproducibility. We deal with bio-peptide drugs, and are designed to maintain its efficacy for 1 to 6 months or longer. AULBIO is focusing on the fields of diabetes, obesity and prostate cancer using drug delivery technology with global competitiveness. Specially, we have been researching semaglutide, tirzepatide, and exenatide long acting injectables for treatment of obesity and diabetes respectively.